文献速递脑血管病头痛与眩晕

对合并卵圆孔未闭的偏头痛患者使用噻吩吡啶类药物治疗的回顾性分析

Retrospective review of thienopyridine therapy in migraineurs with patent foramen ovale.
PubMed 文献 · Neurology · 2018-01-01

本文回顾性分析了2011至2017年间因偏头痛合并卵圆孔未闭就诊的患者使用噻吩吡啶类药物的临床经验;136例患者中80例(59%)对氯吡格雷的偏头痛症状应答;45例无应答者中19例经PRU检测血小板抑制不足,其中16例改用普拉格雷后10例转为应答;56例应答者接受卵圆孔未闭封堵,94%偏头痛缓解持续。

要点

  • 氯吡格雷治疗偏头痛合并卵圆孔未闭患者的偏头痛应答率为59%(80/136)。
  • 血小板抑制不足的无应答者改用普拉格雷后62%(10/16)转为偏头痛应答。
  • 噻吩吡啶类应答者行卵圆孔未闭封堵后94%偏头痛缓解持续,停药未封堵者症状均复发。

核心结论

  • 成功的P2Y12血小板抑制似乎可减轻部分合并卵圆孔未闭的偏头痛患者的偏头痛症状,提示血小板相关机制或触发因素;封堵术后的近乎平行应答可能将静脉血小板激活与卵圆孔未闭的右向左分流机制联系起来;噻吩吡啶类应答性可用于富集新的偏头痛合并卵圆孔未闭试验的研究人群。
  • 本研究提供IV级证据表明,在卵圆孔未闭患者中,P2Y12抑制改善了偏头痛症状。

研究设计与样本

  • 回顾性分析2011至2017年间转诊至本研究中心、因偏头痛接受氯吡格雷超说明书治疗的合并卵圆孔未闭患者,共136例(女性86%,平均年龄37.9岁,平均偏头痛负荷14.7天/月)。

主要发现

  • 80/136(59%)患者为氯吡格雷偏头痛应答者,应答率在发作性、慢性、有先兆和无先兆亚组中相当。
  • 45例偏头痛无应答者中19例(40%)经PRU检测显示氯吡格雷血小板抑制不足,其中16例接受普拉格雷后PRU显示血小板抑制充分,10/16(62%)转为偏头痛应答。
  • 90例噻吩吡啶类应答者中56例随后接受卵圆孔未闭封堵,3个月后停用噻吩吡啶类,94%偏头痛缓解持续;未封堵即停药的8/8例应答者偏头痛症状复发。

临床怎么用

  • 作者认为成功的P2Y12血小板抑制似乎可减轻部分合并卵圆孔未闭的偏头痛患者的偏头痛症状。
  • 作者认为对卵圆孔未闭封堵的近乎平行应答可能从机制上将静脉血小板激活与卵圆孔未闭的右向左分流联系起来。
  • 作者认为噻吩吡啶类应答性可用于富集新的偏头痛合并卵圆孔未闭试验的研究人群。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We retrospectively reviewed our clinical experience using off-label thienopyridine agents in patients with migraine headache (MHA) and patent foramen ovale (PFO). METHODS: Between 2011 and 2017, MHA/PFO patients referred to our practice were clinically treated with clopidogrel specifically for MHA. Those with ≥50% reduction in monthly MHA days compared with baseline were deemed MHA responders. MHA nonresponders with inadequate platelet inhibition by PRU testing were offered prasugrel. Thienopyridine-responsive patients were then offered PFO closure. RESULTS: Of 136 patients (86% female, mean age 37.9 years, mean MHA burden 14.7 days/month), 80 (59%) were MHA responders to clopidogrel. The clopidogrel responder rate was equivalent in episodic, chronic, aura, and nonaura subgroups. A total of 19/45 (40%) MHA nonresponders had inadequate platelet inhibition by PRU testing on clopidogrel. Sixteen of those patients received prasugrel, were adequately platelet inhibited by PRU, and 10/16 (62%) converted to MHA responders. A total of 56/90 thienopyridine-responsive patients underwent subsequent PFO closure with thienopyridine discontinuation after 3 months. Ninety-four percent had ongoing MHA relief. A total of 8/8 responders who stopped thienopyridine without PFO closure had resumption of MHA symptoms. CONCLUSION: Successful P2Y12 platelet inhibition seemed to reduce MHA symptoms in some patients with PFO, suggesting a platelet-based mechanism/trigger. The nearly parallel response to PFO closure may mechanistically link venous platelet activation with the right-to-left shunt of PFO. Thienopyridine responsiveness could be used to enrich the study population for a new MHA/PFO trial. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in patients with PFO, P2Y12 inhibition improved MHA symptoms.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Sommer RJ, Nazif T, Privitera L, et al. Retrospective review of thienopyridine therapy in migraineurs with patent foramen ovale. Neurology. 2018. PMID: 30478066. doi:10.1212/WNL.0000000000006572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。